News
Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback